Harbour Biomed and Yantai Lannacheng Biotechnology announced a long‑term strategic collaboration to co‑develop next‑generation radionuclide‑drug conjugates for oncology. The partners said the deal combines Harbour Biomed’s discovery capabilities with Lannacheng’s radiochemistry and manufacturing expertise to advance targeted radiopharmaceuticals into clinical development. The collaboration underscores growing industry investment in targeted radionuclide therapies as a complementary modality to antibody and cell‑based approaches.